ATE171945T1 - Benzyloxychinuclidine als substanz p antagonisten - Google Patents

Benzyloxychinuclidine als substanz p antagonisten

Info

Publication number
ATE171945T1
ATE171945T1 AT94919851T AT94919851T ATE171945T1 AT E171945 T1 ATE171945 T1 AT E171945T1 AT 94919851 T AT94919851 T AT 94919851T AT 94919851 T AT94919851 T AT 94919851T AT E171945 T1 ATE171945 T1 AT E171945T1
Authority
AT
Austria
Prior art keywords
pct
c6alkyl
c6alkoxy
sec
halogen
Prior art date
Application number
AT94919851T
Other languages
English (en)
Inventor
Kunio Satake
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE171945T1 publication Critical patent/ATE171945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
AT94919851T 1993-07-15 1994-07-05 Benzyloxychinuclidine als substanz p antagonisten ATE171945T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17560993 1993-07-15

Publications (1)

Publication Number Publication Date
ATE171945T1 true ATE171945T1 (de) 1998-10-15

Family

ID=15999090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919851T ATE171945T1 (de) 1993-07-15 1994-07-05 Benzyloxychinuclidine als substanz p antagonisten

Country Status (10)

Country Link
US (1) US5869499A (de)
EP (1) EP0708771B1 (de)
JP (1) JP2843921B2 (de)
AT (1) ATE171945T1 (de)
CA (1) CA2167198C (de)
DE (1) DE69413822T2 (de)
DK (1) DK0708771T3 (de)
ES (1) ES2121213T3 (de)
FI (1) FI960156A (de)
WO (1) WO1995002595A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
EP1001677A4 (de) * 1997-02-04 2003-01-08 Gen Hospital Corp Verfahren zur behandlung von epidermalen oder dermalen hautzuständen
KR100508626B1 (ko) * 1997-06-27 2005-08-17 니폰 가야꾸 가부시끼가이샤 빈뇨·요실금 치료·예방제 및 트로폰 유도체
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
EP1556054A4 (de) * 2002-05-29 2007-09-05 Univ California Antagonisierende nk1-rezeptoren hemmen den drogenmissbrauch
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
EP1904069B1 (de) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl- und heteroarylsubstituierte tetrahydrobenzazepine und verwendung damit zur wiederaufnahmeblockierung von norepinephrin, dopamin und serotonin
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2145884B1 (de) 2007-04-02 2014-08-06 Msd K.K. Indoledionderivat
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
NZ596104A (en) 2009-05-12 2014-01-31 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
US8375635B2 (en) * 2009-08-26 2013-02-19 Richard Hellinga Apparatus for opening and closing overhead sectional doors
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5631281A (en) * 1989-06-29 1997-05-20 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
ATE154354T1 (de) * 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
DK0505180T3 (da) * 1991-03-22 1997-03-24 Merck & Co Inc Farmaceutisk præparat med højt indhold af ibuprofenlysinat
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
UA26401C2 (uk) * 1991-05-22 1999-08-30 Пфайзер Інк. Заміщеhі 3-аміhохіhуклідиhи
AU3171493A (en) * 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
TW270927B (de) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
ATE188472T1 (de) * 1992-10-28 2000-01-15 Merck Sharp & Dohme 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
JPH06149350A (ja) * 1992-10-30 1994-05-27 Johnson Kk 自走車の誘導システム
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5622950A (en) * 1993-03-01 1997-04-22 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
JPH08508466A (ja) * 1993-03-05 1996-09-10 メルク シヤープ エンド ドーム リミテツド ドーパミンｄ４リガンドとしてのキノロン誘導体
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
GB9409882D0 (en) * 1994-05-18 1994-07-06 Sandoz Ltd Organic compounds
US5621004A (en) * 1994-06-03 1997-04-15 Robert W. Dunn Method for treating emesis
GB9413090D0 (en) * 1994-06-29 1994-08-17 Merck Sharp Benzazepine derivatives compositions containing them and their use in therapy
US5621140A (en) * 1994-12-22 1997-04-15 Syntex (U.S.A.) Inc. Resolution of ibuprofen
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

Also Published As

Publication number Publication date
CA2167198A1 (en) 1995-01-26
DK0708771T3 (da) 1999-06-21
FI960156A0 (fi) 1996-01-12
US5869499A (en) 1999-02-09
EP0708771B1 (de) 1998-10-07
ES2121213T3 (es) 1998-11-16
EP0708771A1 (de) 1996-05-01
JP2843921B2 (ja) 1999-01-06
WO1995002595A1 (en) 1995-01-26
JPH08511028A (ja) 1996-11-19
DE69413822T2 (de) 1999-02-25
FI960156A (fi) 1996-01-12
CA2167198C (en) 1999-03-16
DE69413822D1 (de) 1998-11-12

Similar Documents

Publication Publication Date Title
ATE171945T1 (de) Benzyloxychinuclidine als substanz p antagonisten
DE60127595T2 (de) Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
DE69333143D1 (de) Substituierte chinuclidine als substanz p antagonisten
DE69307340T2 (de) Chinuclidin derivat als substanz p antagonist
FI935134A0 (fi) Substituerade 3-aminokinuklidiner
SE9902987D0 (sv) Novel compounds
IL112778A0 (en) Substituted heterocycles, their preparation and pharmaceutical compositions containing them
ATE236158T1 (de) Bicyclische und tricyclische heteroaromatische verbindungen
JP2013506716A (ja) クロフェレマーなどのプロアントシアニジンオリゴマーを用いて疾患を治療する方法
DE69429591T2 (de) Therapeutisch wirksame Verbindungen
EE03262B1 (et) Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
EP0405436B1 (de) Stickstoff enthaltende Diheterocycloheteroethanoanthracenderivate als antipsychotische Mittel
ATE370147T1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
WO2000048581A3 (en) Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
SE0302666D0 (sv) Novel Compounds
BR0116724A (pt) Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto
DE69811487D1 (de) Benzoesäurederivate und deren medizinische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee